Selenium and Bone Health: Why Two Trials Found Nothing

Selenium looks like it should help aging bones. It supports antioxidant enzymes that limit reactive oxygen species, and those molecules can push bone remodeling toward resorption by activating osteoclasts and impairing osteoblast development. Higher selenium status also tracks with higher bone mineral density in observational studies. Then researchers tested the idea in people with low selenium status. Twice, supplementation raised selenium levels without improving bone turnover markers.

That leaves a practical conclusion: selenium may matter for general nutrition and thyroid function, but current human trial evidence does not support taking selenium specifically to protect bone.

Europe's selenium problem began in the food supply

Many Europeans consume less selenium than adults in parts of North America, largely because selenium content in food depends on the soil where crops grow. European intake fell from roughly 60–63 micrograms per day in the 1970s to 29–39 micrograms per day by the early 2000s, according to Perri et al. In the UK, a switch from North American wheat to European-grown flour reduced the selenium content of a dietary staple.

Typical UK serum selenium concentrations fall around 80–100 micrograms per liter, while population mortality data cited in the selenium trial place the apparent optimum around 120–150 micrograms per liter. Mean dietary intake is about 40 micrograms per day, below recommendations of roughly 60–75 micrograms per day for adults older than 50. Globally, an estimated 0.5–1 billion people have serum selenium below 70 micrograms per liter.

Those figures describe a real nutrition issue, but they do not establish that low selenium causes osteoporosis. A nutrient can be inadequate for one biological process while still failing to change another when supplemented. Bone biology is especially good at making simple stories complicated.

The mechanism made sense

Selenium is required for several selenoproteins, including glutathione peroxidases and thioredoxin reductases. These enzymes help neutralize reactive oxygen species. In experimental models, excess reactive oxygen species can favor osteoclast activity, which breaks down bone, and interfere with osteoblast differentiation, which builds bone.

The proposed chain of events was straightforward: low selenium reduces antioxidant defense; oxidative stress increases bone resorption; restoring selenium reduces that pressure and improves bone remodeling. Preclinical work supports parts of that pathway. The long-term trial report notes that selenium-deficient and selenium-supplemented mice differed in bone microarchitecture and that selenium-related enzymes operate in osteoblasts and osteoclasts. But animal deficiency models often involve severe, sustained depletion. They do not tell us whether correcting modest dietary insufficiency in humans prevents fractures.

Observational studies found an association

The epidemiology gave researchers a reason to run trials. In the OPUS cohort, 1,144 postmenopausal women older than 55 in the UK, France, and Germany had serum selenium and selenoprotein P measured. Higher concentrations were associated with higher bone mineral density at the lumbar spine and total hip, along with lower bone turnover markers. The associations remained after accounting for thyroid hormone status.

Selenoprotein P is a useful marker because it transports selenium in the blood and responds across the deficiency-to-adequacy range. Still, this was an observational cohort. People with higher selenium status may also eat more protein, have more varied diets, exercise more, smoke less, or have resources that improve health in several ways at once. Liver disease and inflammation can also affect selenoprotein P, which leaves room for reverse causation.

A 2023 cross-sectional study by da Fonseca Grili et al. found that higher dietary selenium intake was associated with lower osteoporosis prevalence among postmenopausal Brazilian women after multivariable adjustment. This supports the pattern, but it cannot determine cause and effect. Food-frequency questionnaires estimate intake imperfectly, and selenium in food varies sharply with local soil conditions. Brazilian dietary patterns and selenium exposure also do not map neatly onto those in Europe.

Prospective data have also linked selenium intake with hip-fracture risk in older adults and serum selenium with bone mineral density in men. Together, these findings show that selenium status and bone health often travel together. They do not prove selenium is the driver.

Two randomized trials tested the theory directly

The most informative study was a randomized, double-blind, placebo-controlled trial by Walsh et al. in older postmenopausal women in Sheffield, UK. The trial enrolled 120 women with osteopenia or osteoporosis and baseline serum selenium below 120 micrograms per liter. Participants received placebo, 50 micrograms per day of sodium selenite, or 200 micrograms per day for six months.

The higher dose was expected to raise serum selenium by about 60 micrograms per liter, into the proposed optimal range, and biochemical repletion occurred. That detail matters: the trial did not fail because the supplement never changed selenium status. Yet neither dose changed any measured bone turnover marker, including CTX and P1NP, and neither improved physical-function outcomes. The publication reports no benefit on its primary outcomes.

CTX and P1NP are useful indicators of bone resorption and formation, respectively, but they are surrogate outcomes. Six months is long enough to look for a change in these markers; it is too short to settle whether supplementation changes bone mineral density or fracture risk. Still, if selenium prevented bone loss through the proposed antioxidant mechanism, a shift in turnover markers would have made that claim more credible. None appeared.

A second randomized placebo-controlled trial addressed the obvious question: perhaps six months was simply too brief. Perri et al. followed 481 adults for five years using selenium yeast rather than inorganic sodium selenite. Selenium yeast has a different chemical form and bioavailability profile. It also produced no effect on bone turnover markers at any time point.

These trials do not perfectly duplicate one another, which makes their agreement more informative. They used different selenium forms and sharply different follow-up periods. Both found that selenium supplementation failed to move the bone-turnover outcomes researchers expected to change.

Why the mechanism and trials can disagree

The likely explanation is confounding. Selenium status is partly a marker of a person's overall diet quality, food diversity, protein intake, and socioeconomic circumstances. Each of those factors can influence bone health independently. Observational studies can adjust for some of them, but they cannot fully separate selenium from the broader pattern of living and eating well.

A broader antioxidant strategy has also failed to translate neatly into bone-marker benefits. In an exploratory randomized trial during 60 days of head-down-tilt bed rest, Austermann et al. found that an antioxidant supplement did not alter bone turnover markers despite mechanical unloading and elevated oxidative stress. The model does not resemble ordinary aging, and the intervention was not selenium-specific. It does, however, reinforce a useful lesson: oxidative stress can participate in bone biology without making antioxidant supplementation an effective bone treatment.

Safety narrows the case for high-dose selenium

Walsh and colleagues observed thyroid-stimulating hormone abnormalities in the 200-microgram-per-day group, despite excluding women with known thyroid dysfunction at enrollment. Selenium has a narrow therapeutic window, and thyroid disease is already common in older women. A dose that solves an imagined bone problem can create a real endocrine-monitoring problem.

The proposed U-shaped relationship between serum selenium and mortality adds another reason for restraint. Someone starting around 80–120 micrograms per liter may overshoot with high-dose supplementation. The trial does not establish a safe self-treatment protocol for bone health, and its results do not offer a reason to look for one.

What remains uncertain

Neither randomized trial was designed to detect fractures, and neither specifically targeted people with extreme selenium deficiency below 70 micrograms per liter. It remains technically possible that this smaller, more severely deficient group responds differently. Neither trial also pre-stratified participants by severity within the deficient range.

But uncertainty cuts both ways. There is no trial evidence that selenium prevents fractures in that group, and there was no bone-turnover signal after repletion in the studied populations. The idea remains untested at the fracture endpoint, not supported.

The practical verdict

Do not take selenium supplements for bone health. Two randomized trials—one lasting six months with sodium selenite and one lasting five years with selenium yeast—found no improvement in bone turnover markers despite supplementation. The observational associations are real, but they fit the simpler explanation that selenium status reflects broader nutritional adequacy.

If your diet is likely low in selenium, food is the sensible first move. Seafood and organ meats provide selenium, and Brazil nuts are exceptionally concentrated sources; because their selenium content varies, two to three nuts per week is more prudent than treating them like trail mix. Discuss testing or supplementation with a clinician if you have a documented deficiency, thyroid disease, malabsorption, or another medical reason to manage selenium status. For preserving bone, prioritize interventions with established clinical relevance: resistance and impact exercise when appropriate, adequate protein and calcium, correction of vitamin D deficiency, fall prevention, and osteoporosis evaluation when risk warrants it.